CCL5 and COVID-19: Based on our results, we suggest that controlling high-severity-specific markers (FOS, CXCL8, HLA-A, JAK3, ICAM1, and H2BC4) and low-severity-specific markers (IL1B, CD3D, CD4, CCL5, and SNRPB) may prevent COVID-19 progression.